New JAK Inhibitor Study Data Confirm Benefit in Alopecia Areata New JAK Inhibitor Study Data Confirm Benefit in Alopecia Areata
The investigational drug deuruxolitinib is effective for hair regrowth in patients with alopecia areata, putting it in line to become second approved JAK inhibitor.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 24, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Increased risk of suicide attempt in patients with alopecia areata: a nationwide population-based cohort study - Wang LH, Ma SH, Tai YH, Dai YX, Chang YT, Chen TJ, Chen MH.
BACKGROUND: There is growing evidence that patients with alopecia areata (AA) have an increased risk of developing psychiatric comorbidities. However, the relationship between AA and suicidal behaviors remains unclear. OBJECTIVE: To investigate the... (Source: SafetyLit)
Source: SafetyLit - March 20, 2023 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
Another Win for a JAK Inhibitor in Alopecia Areata
(MedPage Today) -- NEW ORLEANS -- Patients with severe alopecia areata had dramatic hair regrowth at 6 months with an investigational Janus kinase (JAK) inhibitor, according to a study reported here.
Almost 40% of patients had at least 80% scalp... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 20, 2023 Category: Dermatology Source Type: news
Hair Regrowth Seen in Alopecia With Methotrexate + Prednisone
WEDNESDAY, March 15, 2023 -- For patients with recalcitrant alopecia areata totalis or universalis, methotrexate combined with prednisone yields complete hair regrowth in about 31 percent of patients, according to a study published online March 8 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 15, 2023 Category: Pharmaceuticals Source Type: news
From Patient to Physician: Current Perspectives on the Complexities of Alopecia Areata From Patient to Physician: Current Perspectives on the Complexities of Alopecia Areata
Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Burden of Alopecia Areata Significant in the United States
MONDAY, March 6, 2023 -- The burden of alopecia areata (AA) is considerable in the United States, with people of color, especially Asians, disproportionately affected, according to a study published online March 1 in JAMA Dermatology.
Nene Sy, from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 6, 2023 Category: Pharmaceuticals Source Type: news
Sun Pharma completes acquisition of Concert Pharmaceuticals
The drug major has successfully completed the acquisition of Concert Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company that is developing deuruxolitinib for the potential treatment of adult patients with moderate to severe alopecia areata, Sun Pharma said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 6, 2023 Category: Pharmaceuticals Source Type: news
High Rates of Psychiatric Disorders in Patients With Alopecia Areata
(MedPage Today) -- Patients with alopecia areata (AA) had rates of anxiety and depression two to three times higher than the general population, and more than a third had suggestive symptoms, according to a meta-analysis of published data.
The... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - February 1, 2023 Category: Psychiatry Source Type: news
Sun Pharma to buy concert for $576 m
Concert has pioneered the use of deuterium (a hydrogen isotope) in medicinal chemistry and has an extensive patent portfolio, including its lead product candidate deuruxolitinib - an oral inhibitor that blocks Janus kinases JAK1 and JAK2 for the treatment of baldness. Concert has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase 3 clinical program and two open label, long-term extension studies are ongoing in North America and Europe. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 20, 2023 Category: Pharmaceuticals Source Type: news
Sun Pharma to acquire US-based Concert for $576 million
Concert's lead candidate, deuruxolitinib, is being evaluated as a treatment for autoimmune condition alopecia areata, which results in patchy hair loss. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 19, 2023 Category: Pharmaceuticals Source Type: news
Study Evaluates Alopecia Areata Features in Hispanic Population Study Evaluates Alopecia Areata Features in Hispanic Population
In the study, the most common comorbidity in patients overall was atopy, including allergic rhinitis, asthma, and/or atopic dermatitis.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 29, 2022 Category: Dermatology Tags: Dermatology News Source Type: news
Alopecia Areata: Positive Data Reported for Two JAK Inhibitors Alopecia Areata: Positive Data Reported for Two JAK Inhibitors
JAK inhibitor therapy is hailed as"transformative" for patients with alopecia areata by one of the investigators reporting study results.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 29, 2022 Category: Dermatology Tags: Dermatology News Source Type: news
FDA and EMA Accept Regulatory Submission for Pfizer ’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata
Filings based on clinical data demonstrating significant scalp hair regrowth versus placebo
NEW YORK--(BUSINESS WIRE) September 09, 2022 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 9, 2022 Category: Drugs & Pharmacology Source Type: news
Future Is Brighter for Alopecia Treatment: Expert
For many people with severe alopecia areata, who have lived with baldness, or with scalps only sparsely dotted with hair, or with missing eyebrows or lashes, the future has a new look. (Source: WebMD Health)
Source: WebMD Health - July 19, 2022 Category: Consumer Health News Source Type: news
Baricitinib for Alopecia Areata: Starting Patients on Treatment Baricitinib for Alopecia Areata: Starting Patients on Treatment
Physicians should be ready for questions on who should get the drug, how fast it works, and what patients should consider regarding the label ' s boxed warning.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 2, 2022 Category: Dermatology Tags: Dermatology News Source Type: news
